HealthStream, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-58.9% vs price
Base Case (Median)
-43.9% vs price
Bull Case (75th pct.)
-4.1% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.85 | -93.5% | High (40%) |
| PE Comparable | $16.03 | -43.9% | Medium (25%) |
| Growth Trajectory DCF | $35.38 | 23.9% | Medium (20%) |
| Graham Number | $13.82 | -51.6% | Medium (40%) |
| EV/EBITDA | $22.22 | -22.2% | Medium (20%) |
| EV/FCF | $32.55 | 14.0% | Medium (20%) |
| Earnings Power Value | $9.63 | -66.3% | Medium (50%) |
Based on 7 out of 8 methods, HSTM appears overvalued at the current price of $28.55. The base case fair value of $16.03 implies 43.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.